Search

Displaying results 3091 - 3100 of 10000 in total
  1. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status. … Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme.

    Categories: Receptor Protein-Tyrosine Kinases, antagonists & inhibitors
  2. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Telaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label]. … Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  3. Target

    Malate dehydrogenase, cytoplasmic

    go.drugbank.com/bio_entities/BE0000589
    TargetHumans

    Catalyzes the reduction of aromatic alpha-keto acids in the presence of NADH (PubMed:2449162, PubMed:3052244). Plays essential roles in the malate-aspartate shuttle and the tricarboxylic acid cycle, important in mitochondrial NADH supply...

    Synonyms: KAR
  4. Drug

    Lutein

    go.drugbank.com/drugs/DB00137
    ApprovedNutraceutical

    Lutein is an xanthophyll and one of 600 known naturally occurring carotenoids. … In green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very

  5. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … NS5B, an RNA-dependent RNA polymerase, is essential for the transcription of Hepatitis C viral RNA and for its high replicative rate and genetic diversity [A19594].

    Products: I-HEP SOBOVIR
  6. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)

  7. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions [A32046 … It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.

  8. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    [L10866] In non-human primate clinical trials, the vaccine was effective in inducing an immune response against the Ebola viruses. … Ervebo consists of an envelope glycoprotein of the Zaire ebolavirus (Kikwit 1995 strain) fused into a vesicular stomatitis virus (VSV) backbone.

  9. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … [L64050,L64051] It is administered as a single, one-time intravenous infusion.

  10. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    Palopegteriparatide is a parathyroid hormone (PTH) analog. … [A264199] Upon administration, PTH is cleaved from palopegteriparatide in a controlled manner to achieve a continuous systemic exposure of active PTH.